T-Space at The University of Toronto Libraries >
School of Graduate Studies - Theses >
Please use this identifier to cite or link to this item:
|Title: ||Cost-effectiveness of Intravenous Antibiotics in Moderate to Severe Diabetic Foot Infections and Efficacy as a Function of Resistance Rates in the Case of Methicillan-resistant Staphylococcus Aureus in Diabetic Foot Infections|
|Authors: ||Marchesano, Romina|
|Advisor: ||Einarson, Thomas Ray|
|Department: ||Pharmaceutical Sciences|
|Keywords: ||Cost-effectiveness analysis|
Diabetic foot infection
|Issue Date: ||22-Nov-2012|
|Abstract: ||Objectives: The objectives of the research were to determine which intravenous (IV) antibiotics were cost-effective in Diabetic Foot Infections (DFIs) and to assess the impact of MRSA prevalence on clinical outcome.
Methods: A Cost-effectiveness analysis (CEA) was performed on IV antibiotics used to treat moderate to severe DFIs in hospitalized patients. MRSA prevalence was taken into account by calculating an ‘Adjusted cure rate’ and re-analysing the CEA.
Results: In the original CEA, imipenem/cilastatin was the cost-effective agent. When MRSA prevalence was taken into account imipenem/cilastatin, moxifloxacin, cefoxitin and ertapenem were cost-effective antibiotics.
Conclusion: MRSA prevalence adjustments changed the results of the CEA and included classes of IV antibiotics that are seen being using in practice, such as fluoroquinolones and cephalosporins. These methods could potentially have an impact on the evaluation of clinical cure rates and resistance when evaluating the literature.|
|Appears in Collections:||Master|
This item is licensed under a Creative Commons License
Items in T-Space are protected by copyright, with all rights reserved, unless otherwise indicated.